WHAT IS CLAIMED IS:

having the primary structural conformation and biological properties of naturally-occurring metalloproteinase inhibitor.

- A polypeptide according to Claim 1
 wherein said polypeptide is the product of procaryotic
 or eucaryotic expression of an exogenous DNA sequence.
 - 3. A polypeptide according to Claim 1 further characterized by being free of association with any mammalian protein.

4. A polypeptide according to Claim 2 wherein the exogenous DNA sequence is a cDNA sequence.

- 5. A polypeptide according to Claim 2
 20 wherein the polypeptide is bovine metalloproteinase inhibitor.
- 6. A polypeptide according to Claim 2 wherein the exogenous DNA sequence is a genomic DNA sequence.
 - 7. A polypeptide according to Claim 2 wherein the exogenous DNA sequence is carried on an autonomously replicating DNA plasmid or viral vector.
 - 8. A polypeptide according to Claim 1 possessing part or all of the primary structural conformation of human metalloproteinase inhibitor as set forth in Figure 2 or any naturally occurring allelic variant thereof.

30

35

. 3

- 9. A polypeptide according to Claim 1 which has the immunological properties of naturally-occurring metalloproteinase inhibitor.
- 5 10 A polypeptide according to Claim 1 which has the <u>in vitro</u> biological activity of naturally-occurring metalloproteinase inhibitor.
- 11. A polypeptide according to Claim 1
 10 further characterized by being covalently associated
 with a detectable label substance.
- expression in a procaryotic or eucaryotic host cell of a polypeptide product having at least a part of the primary structural conformation and one or more of the biological properties of naturally-occurring metalloproteinase inhibitor, said DNA sequence selected from among:
- 20 (a) the DNA sequence set out in Figure 1 or Figure 2 or their complementary strands;
 - (b) DNA sequences which hybridize to the DNA sequences defined in (a) or fragments thereof; and
- (c) DNA sequences which, but for the degeneracy of the genetic code, would hybridize to the DNA sequences defined in (a) and (b).
- 13. A procaryotic or eucaryotic host cell transformed or transfected with a DNA sequence according to Claim 12 in a manner allowing the host cell to express said polypeptide product.
- 14. A polypeptide product of the expression of a DNA sequence of Claim 12 in a procaryotic or 35 eucaryotic host.

- Do. A purified and isolated DNA sequence coding for procaryotic or eucaryotic host expression of a polypeptide having the primary structural conformation and biological properties of metalloproteinase inhibitor.
 - 16. A\cDNA sequence according to Claim 15.
- 17. A genomic DNA sequence according to 10 Claim 15.
 - 18. A DNA sequence according to Claim 15 wherein said DNA sequence codes for human metalloproteinase inhibitor.
 - 19. A DNA sequence according to Claim 18 and including one or more codons preferred for expression in \underline{E} . \underline{coli} cells.
- 20. A DNA sequence according to Claim 15 having the sequence set out in Figure 2.
- 21. A DNA sequence according to Claim 15 and including one or more codons preferred for expression in 25 yeast cells.
 - 22. A DNA sequence according to Claim 15 covalently associated with a detectable label substance.
- 30 23. A DNA sequence coding for a polypeptide fragment or polypeptide analog of naturally-occurring metalloproteinase inhibitor.
- 24. A DNA sequence as in Claim 23 coding for 35 methionyl metalloproteinase inhibitor.

. }

25. A biologically functional plasmid or viral DNA vector including a DNA sequence according to Claim 12.

- 5 26. A procaryotic or eucaryotic host cell stably transformed or transfected with a DNA vector according to Claim 25.
- 27. A polypeptide product of the expression 10 in a procaryotic or eucaryotic host cell of a DNA sequence according to Claim 15.
- 78. A synthetic polypeptide having part or all of the amino acid sequence as set forth in Figure 2 and having one or more of the <u>in vitro</u> biological activities of naturally-occurring metalloproteinase inhibitor.
- 29. A synthetic polypeptide having part or 20 all of the secondary conformation of part or all of the amino acid sequence set forth in Figure 2 and having a biological property of naturally-occurring human metalloproteinase inhibitor.
- 25
 30. A process for the production of a polypeptide having part or all of the primary structural conformation and one or more of the biological properties of naturally occurring metalloproteinase inhibitor, said process comprising:
- growing under suitable nutrient conditions, procaryotic or eucaryotic host cells transformed or transfected with a DNA vector according to Claim 25, and isolating desired polypeptide products of the expression of DNA sequences in said vector.

- 31. Purified and isolated human metalloproteinase inhibitor free of association with any human protein in glycosylated or nonglycosylated form.
- 32. A pharmaceutical composition comprising an effective amount of a polypeptide according to Claim 1 and a pharmaceutically acceptable diluent, adjuvant or carrier.
 - 33. A method for inhibiting tumor cell dissemination in a mampal comprising administering an effective amount of a polypeptide according to Claim 1.
- 34. A method for treating rheumatoid

 15 arthritis in a mammal comprising administering an effective amount of a polypeptide according to Claim 1.
 - 35. A DNA sequence coding for an analog of human metalloproteinase inhibitor selected from the group consisting of:
 - a) [Met-1] metalloproteinase inhibitor; and
 - b) metalloproteinese inhibitor wherein one or more cysteines are replaced by alanine or serine.
- 25 36. A polypeptide product of the expression in a procaryotic or eucaryotic host cell of a DNA sequence according to Claim 35.
- 37. A preparation of MI which is greater than 30 95% pure and which comprises less than 0.5 ng of pyrogen per 0.5 mg of metalloproteinase inhibitor.
 - 38. An antibody specifically binding metalloproteinase inhibitor.

35

10

39. An antibody as in Claim 38 wherein said antibody is a monoclonal antibody.

5

odd at

add

10

15

20

25

30